On 6 May 2025, UK-based chemicals group Synthomer announced the divestment of William Blythe Limited, its inorganic chemistry subsidiary, to the company’s management team supported by H2 Equity Partners. The purchase price is GBP 30 million, equivalent to around EUR 35 million. Founded in 1845, William Blythe specialises in developing and manufacturing inorganic derivatives based on elements such as tin, iodine, copper, zinc and tungsten. In the financial year ending 31 December 2024, the company generated sales of GBP 54 million and stand-alone adjusted EBITDA of GBP 4 million. CEO Michael Willome stated that while William Blythe has delivered strong performance over many years, the business offers limited synergies with the rest of the Group.